Pathogenesis and progression of monoclonal gammopathy of undetermined significance

被引:66
作者
Blade, J. [1 ]
Rosinol, L. [1 ]
Cibeira, M. T. [1 ]
de Larrea, C. F. [1 ]
机构
[1] Univ Barcelona, Dept Hematol, Inst Hematol & Oncol, IDIBAPS,Hosp Clin, Barcelona, Spain
关键词
monoclonal gammopathy of undetermined significance; smouldering multiple myeloma; malignant transformation;
D O I
10.1038/leu.2008.203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In Caucasians, monoclonal gammopathy of undetermined significance (MGUS) is an age-related condition with prevalence as high as 3% in persons older than 50 years. Compared with whites, blacks have around two-and threefold higher prevalence rates of MGUS and multiple myeloma (MM), respectively. Risk of progression from MGUS to MM has been found to be very similar in whites and blacks. On average, the transformation rate to a malignant monoclonal gammopathy is 1% per year, with the mechanisms of progression likely related to bone marrow microenvironment and/or the cytokine network. Overall, the actuarial probability of progression at 25 years of follow-up is about 30%. However, when the competing causes of death are taken into account, the actual rate of progression is only 11%. The predictors of malignant transformation are the plasma cell mass (M-protein size and/or proportion of plasma cell in the bone marrow), IgA isotype, serum free light-chain ratio and 'evolving' type and ratio between phenotypically aberrant and normal bone marrow plasma cells. It is recommended to follow these patients, particularly those with high risk of progression, annually to detect MM before complications, such as renal failure or extensive skeletal, involvement occur.
引用
收藏
页码:1651 / 1657
页数:7
相关论文
共 63 条
  • [1] AGUZZI F, 1992, EUR J HAEMATOL, V48, P192
  • [2] AXELSSON U, 1986, ACTA MED SCAND, V219, P519
  • [3] AXELSSON U, 1966, ACTA MED SCAND, V179, P235
  • [4] Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy
    Baldini, L
    Guffanti, A
    Cesana, BM
    Colombi, M
    Chiorboli, O
    Damilano, I
    Maiolo, AT
    [J]. BLOOD, 1996, 87 (03) : 912 - 918
  • [5] CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
    Bataille, Regis
    Pellat-Deceunynck, Catherine
    Robillard, Nelly
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    Moreau, Philippe
    [J]. LEUKEMIA RESEARCH, 2008, 32 (03) : 379 - 382
  • [6] BERGSAGEL PL, 2004, MYELOMA BIOL MANAGEM, P35
  • [7] MALIGNANT TRANSFORMATION AND LIFE EXPECTANCY IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE
    BLADE, J
    LOPEZGUILLERMO, A
    ROZMAN, C
    CERVANTES, F
    SALGADO, C
    AGUILAR, JL
    VIVESCORRONS, JL
    MONTSERRAT, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (03) : 391 - 394
  • [8] On the "Significance" of monoclonal Gammopathy of undetermined significance
    Bladé, J
    [J]. MAYO CLINIC PROCEEDINGS, 2004, 79 (07) : 855 - 856
  • [9] Interleukin 6 and tumour necrosis factor alpha serum levels in monoclonal gammopathy of undetermined significance
    Bladé, J
    Filella, X
    Montoto, S
    Bosch, F
    Rosiñol, L
    Coca, F
    Giné, E
    Nadal, E
    Aymerich, M
    Rozman, M
    Montserrat, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) : 387 - 389
  • [10] Clinical practice:: Monoclonal gammopathy of undetermined significance
    Blade, Joan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (26) : 2765 - 2770